Presenting Companies
Adhera Health delivers a next-generation AI Health Agentic Platform for pediatric chronic care management, empowering families with intelligent, real-time support tailored to both the child’s condition and the family caregiver’s needs. Our platform is powered by Adhera Health Agents—goal-driven, autonomous AI entities built on proprietary Small Language Models (SLMs) and informed by family-centered biopsychosocial data. This personalized, transdiagnostic approach enables emotionally intelligent micro-interventions that improve engagement, adherence, and emotional well-being. Adhera Health drives better clinical outcomes for the whole family while reducing healthcare costs for providers, payors, and self-funded employers.
Patients with advanced heart failure urgently require more effective and safer mechanical circulatory support (MCS) solutions, as existing technologies are linked to severe blood-related complications like strokes and bleeding, limiting their widespread use. AdjuCor's reBEAT system directly addresses this critical unmet need with a groundbreaking, non-blood-contacting technology. The system uses a custom-fit implant with pneumatically inflatable cushions to augment the weakened heart's performance in sync with its natural rhythm. This minimally invasive approach uniquely avoids blood contact, offering the potential for significantly fewer complications and faster patient recovery compared to current MCS options, serving a large and underserved market. reBEAT aims to enter the market in a mid-term application indication (tMCS for BTT <30 days) - not covered by any other treatment, although off-label use persists. This strategy is a stepping stone to achieving the target market of expanding into even longer-term support (>30 days), thereby becoming a tool for physicians with which not only advanced HF patients can be treated (needing LVAD/HTX), but also the large population of stage C2D that requires a long-term, safer type of mechanical support.
Amplifi’s first-of-its-kind Vein Dilation System is a $4B New Market Opportunity in the $10B hemodialysis (HD) segment set to expand patient accessibility and speed to maturation to the Gold Standard forearm arterio-venous fistula (AVF). 70% of long-term hemodialysis is administered with an inferior solution (dialysis catheter, graft, upper arm fistula). The U.S. patient population requiring HD 2-3x each week is ~800,000. Access for these patients to the National Kidney Foundation’s “first choice” (Gold Standard) “forearm AVF” is severely limited by success rates for this modality. Vein size is most closely correlated with forearm AVF success rates (diameter of <2.7mm ~ 35%; ≥4.1mm ~75%).
ANEUVO is a bioelectronic medicine company developing non-invasive neuromodulation therapies to restore function for people with chronic neurological conditions. Its lead product, ExaStim®, is a wireless, non-surgical spinal cord stimulation system designed to improve motor function for individuals with spinal cord injury (SCI).
Atmo is a clinical stage digital health business focused on empowering researchers, clinicians and patients with objective real-time insights into gut health and microbiome function
Our mission is to change the lives of cancer patients by transforming their journey. We have created a unique diagnostic platform designed specifically for specialty physician and oncologist offices. We have successfully brought together the speed and cost of point-of-care platforms combined with the accuracy and quality of core lab instruments. The platform will allow physicians to diagnosis while their patient is in office eliminating extra office visits for the patient and accelerating the path to treatment.
AURA Health Technologies develops AI-powered surgical guidance systems for breast cancer surgery. AURA’s IntraGuide technology integrates seamlessly with existing ultrasound systems to detect biopsy clips (placed in the breast at diagnosis) in real time during surgery, eliminating invasive pre-surgical procedures and improving surgical precision. By providing precise surgical guidance and eliminating pre-surgical localization methods, AURA reduces healthcare costs, streamlines scheduling, and eliminates patient discomfort from additional procedures. The company is advancing direct tumor visualization capabilities through government-funded research, targeting the critical challenge of achieving clear margins—an issue that leads to 15-35% re-operation rates globally.
BOYDSense, an award-winning start-up developing non-invasive breath analysis solutions to risk stratify, monitor and detect biomarkers for chronic conditions and diseases, focusing initially on Diabetes. We're a pioneering business (with corporate roots in Delaware, US) with a European headquarters located in Toulouse, France. We have additional operations in San Francisco. The first product to market is a miniaturized pain free breath analyzer to monitor glucose levels in pre-diabetics and type 2 diabetics non-invasively. Unlike existing blood glucose monitors, our solution is pain-free and has proven clinical performance for the target group.
Cordio developed the HearO® software as medical device system that enables heart failure monitoring through advanced AI-assisted speech processing technology. HearO® is using only the patient’s speech sampled via his mobile device. HearO® is CE approved with FDA breakthrough device designation medical device and is a few months shy of its FDA approval. HearO® has strong clinical validation (more than 1500 patients in various studies), valid US reimbursement, and a strong business model. Cordio is currently gearing up toward the HearO US launch.
Cosm Medical is digitizing gynecological devices to personalize care for pelvic health issues that affect half of all women in their lifetime. Advancing a digital platform that combines AI, cloud software, and 3D printing, Cosm partners with clinicians to improve care with personalized gynecological devices. Their first products, Digital Gynecology Software & Gynethotics Pessaries (Health Canada & FDA cleared), provides clinicians and patients with access to the world's first personalized pessary, or gynecological prosthetic, to manage symptoms of prolapse and incontinence. Beyond pessaries, Cosm is ushering in an age of digital gynecology from obstetrics to surgery and elderly care. They are on their way to making ‘Invisalign for Pelvic Health’ a reality having achieved major milestones on the path to creating a new product category like the billion-dollar markets of custom orthotics, dental and hearing.
Darmiyan is a San Francisco-based neuroscience and AI company revolutionizing brain health. Its flagship product BrainSee is the first and only FDA-approved tool for predicting dementia. It leverages proprietary virtual microscope technology and advanced AI to provide non-invasive and highly accurate prognosis for patients at risk of Alzheimer’s disease. Darmiyan's other product, DarmiSpace, is the first neuroscience-based and evidence-based platform to assess and improve lifestyle, enhance brain health, and prevent dementia in the general public.
At Dasion we are utilizing novel Geometric Unified Learning (GUL) to bring fast, interpretable decision making tools to healthcare practitioners, reinventing the relationship between AI and medicine. We build systems that expedite health data interpretation and diagnosis, allowing healthcare professionals to spend more time doing what they do best, caring for their patients.
Our first solution enables sonographers to scan patients from hundreds of miles away using off-the-shelf robotic ultrasound hardware. By transforming care delivery from weeks to minutes, Dopl eliminates geographic barriers and brings high-quality imaging to underserved communities. The result is faster diagnoses, improved outcomes, and greater healthcare equity. Dopl is already delivering outreach ultrasound services in rural hospitals, with demonstrated improvements in workflow efficiency, patient delays, and patient/provider satisfaction.
At Freespira, we are focused on improving access to care through our unique at-home behavioral health treatment with FDA-cleared indications for PTSD and panic disorder symptoms. The treatment combines a medical device with high-touch support to deliver rapidand lasting symptom relief in just 28 days.
Frond Medical is a Silicon Valley medtech startup founded by two former Boston Scientific R&D engineers. Through a strong strategic partnership with a global interventional leader, we’ve developed a breakthrough lung biopsy platform that reaches the 10th airway generation, far beyond current clinical capabilities, powered by our proprietary imaging and real-time sub-millimeter position sensing, featuring the deepest nodule accessibility and highest resolution in the world. This leap in access and precision aims to transform lung cancer diagnosis and enable earlier, more effective treatment for millions.
RNA AI Platform for Next Generation Cures (Platform as a Service) saving lives today and bending the cost and time curve for drug discovery and development in the future. Biological software company enabling RNA AI at scale.
.png){kind=logo}
Currently used liver tests estimate the extent of fibrosis, missing the compensatory effects of liver regeneration and increased blood flow to extant functioning tissue. HEPATIQ quantifies remaining liver function thus improving prediction of disease outcomes. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank. HEPATIQ is FDA cleared and the only quantitative liver function product commercially available for routine use. The scan is covered by the patient's insurance.
MediLexis.AI is a regulatory advisor AI tool enabling faster time to market and faster development cycles for medtech innovators and consulting groups by providing regulatory pathways for FDA and EU (CE mark under MDR rules) for medical devices. Medilexis.AI also optimizes predicate search and Q&A on regulatory standards, accelerating a process that could take weeks to mere minutes. MediLexis.AI is looking for partners and angels/early stage VC at the conference. A live demo will be available.
MindBio Therapeutics Corp (CSE:MBIO) is a clinical stage biotech/biopharma company that has developed a take-home non-hallucinogenic microdose formulation of a psychedelic medicine to treat depressive illnesses. Currently in multiple late state Phase 2B clinical trials, the company has developed novel technologies and software prediction tools for drug intoxication detection using machine learning and artificial intelligence.
Nano4Imaging (N4I) developed the TRACKR technology, enabling real-time MRI-guided endovascular procedures. TRACKR addresses the rapidly growing new market of Interventional MRI (iMRI). The company is based in Düsseldorf, Germany, with a subsidiary in Dublin, Ohio, USA.
NeuroOne’s robust product suite offers acute diagnostic neurology and chronic treatment solutions for epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with three FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes and OneRF® Ablation System. NeuroOne technologies offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. NeuroOne recently filed its 510(k) submission to the FDA for trigeminal nerve ablation. The Company is engaged in research and development for drug delivery and spinal cord stimulation (SCS) programs and is exploring other applications of its technology.
NEXT Life Sciences is modernizing reproductive healthcare with a portfolio of derisked, high-impact medical devices and pharmaceutical products. Most notably and publicly shared includes Plan A, the only long-lasting, reversible (on demand), non-hormonal male birth control, and NLS-811, the only medicated erectile dysfunction cream (ED). NEXT’s Management team has generated billions of dollars in investor returns. Some key executives: Dr. Darlene Walley (fmr. women’s health CEO with $1B in exits), Steve Bacich (fmr. contraceptive CEO with a $1B exit), Dr. Bob Dudley (fmr. men’s health CEO with $1B/yr revenue), and other industry leaders.
Ausa Health by Prar addresses the critical need for affordable, convenient, and seamless primary care consultations at home.
Pristine Surgical is a medical device company with a mission to simplify endoscopy. The company combines single-use endoscopes with cloud-based software to make minimally invasive visualization more efficient, consistent, and safe. Pristine Surgical offers a subscription business model with transparent pricing and automated inventory management, delivering improved workflow and reduced costs to the endoscopy suite.
SageMedic develops a genome-free SAGE Direct Platform that introduces the next generation of precision medicine by directly testing effective cancer treatments on a live tissue biopsy of a patient.
Shape Memory Medical is a California-based medical device company that is focused on endovascular markets with its proprietary shape memory polymers, or “smart polymer.” With commercialized devices in peripheral vascular embolization space, the Company is actively leveraging its platform technology to develop novel applications for the management of complex aortic pathologies including aortic aneurysms and aortic dissection.
Silicon Valley Innovations (SVI) presents a unique investment opportunity at the intersection of clinical medicine and the exploding $4.5 Trillion personal healthcare market. The team has a proven, impressive track record with more than 30 years of expertise in medical device development bringing ground-breaking products to market and yielding multiple successful exits totaling nearly $500M. The company is now creating patent protected, clinically validated, FDA registered medical device platform technologies to optimize health through clinical and consumer facing products. Current and future products include an extensive portfolio in two robust target markets (respiratory & women’s healthcare). Included are preventive self-health platforms, as well as future drug treatment/delivery systems. Currently, SVI is focused on the commercial launch of its flagship product, NasoClenz® - a breakthrough self-health solution poised to capture a significant portion of the $71 billion respiratory care sector.
SIME is a clinical AI platform company that provides data-driven and precise insights to doctors in decisive moments.
SOMAVAC’s discreet negative pressure therapy system for seroma prevention helps patients get back on their feet sooner, more comfortably, and with dignity. By pulling fluid continuously out of the deep tissue, the SOMAVAC® therapy system replaces outdated manual suction bulbs, streamlines the recovery process, and significantly reduces the incidence of seromas in large flap surgeries. SOMAVAC is transforming the status quo of post-surgical fluid removal and impacting breast cancer patients’ lives for the better.
Stroma Medical Corporation is a pre-revenue, clinical-stage medical device startup company raising a Series C preferred equity round. The company has developed an ophthalmic aesthetic laser technology for the permanent change of eye color. The technology benefits from the rapidly growing market for aesthetic procedures while bypassing the challenges associated with reimbursement. Stroma has completed a series of clinical studies and is preparing to start a pivotal study in Europe in 2026. Stroma is currently raising a $25 million Series C round to support the pivotal study, company operations, and product launch.
SurgiBox is a medtech innovator founded at Harvard and incubated at MIT; SurgiBox's SurgiField is the first of its kind ultraportable operating field. SurgiField is a TIME Best Inventions of 2023 awardee, a Harvard President's Challenge Grand Prize and MassChallenge Platinum awardee, as well as a design award recipient from London Design Museum for its innovative technology. SurgiBox has been awarded patents in over 20 countries and has raised from VC, Institutional, and Strategic investors. SurgiBox is raising a commercialization Series A to enable its market launch internationally.
Torramics is developing the smallest, most precise, and most reliable, automated drug delivery platform, leveraging pneumatically actuated nanofluidic pumps powered by breakthrough semiconductor-based air compressor technology originally developed at NASA.
Vitazi.ai is a precision health company revolutionizing chronic disease detection through noninvasive, AI-powered retinal imaging. Our platform analyzes high-resolution retinal photographs to identify biomarkers linked to diabetes, hypertension, cardiovascular disease, and more, offering early insight into systemic health. By integrating seamlessly into primary care, optometry, and lab workflows, Vitazi.ai helps close care gaps and improve outcomes across populations. We empower providers and payers with actionable, scalable tools to drive preventive care and value-based performance.